|

Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia

RECRUITINGSponsored by Peking University People's Hospital
Actively Recruiting
SponsorPeking University People's Hospital
Started2025-06-01
Est. completion2026-04-07
Eligibility
Age6 Years – 60 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07537738

Summary

The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement. The main question it aims to answer is: • Could be leukemia stem cell used for relapse prediction in acute myeloid leukemia patients with MLL-rearrangement? Leukemia stem cell will be detected at the same time for participants who detected minimal residual disease using bone marrow as part of their regular medical care to answer the question.

Eligibility

Age: 6 Years – 60 YearsHealthy volunteers accepted
Inclusion Criteria:

Acute myeloiud leukemia patients with MLL arrangement aging 6-60 years recieving chemoterapy or allo-geneic hematopoietic stem cell transplantation.

Exclusion Criteria:

1. Patients who cannot recieve chemoterapy or allo-geneic hematopoietic stem cell transplantation.
2. Patients who cannot comply with the study.

Conditions3

Acute Myeloid Leukemia (AML)CancerMLL Rearrangement

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.